Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) shares traded up 12.4% during trading on Friday . The company traded as high as $2.23 and last traded at $2.00, with a volume of 3,708,331 shares changing hands. The stock had previously closed at $1.78.

A number of research analysts have recently commented on the company. Zacks Investment Research downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, May 3rd. Stifel Nicolaus downgraded Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 13th. Jefferies Group reiterated a “buy” rating and set a $2.50 target price (down from $13.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 14th. Finally, Royal Bank Of Canada downgraded Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $14.00 to $2.00 in a research report on Tuesday, June 14th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.80.

The company’s market capitalization is $39.02 million. The stock has a 50 day moving average price of $2.69 and a 200 day moving average price of $4.76.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. Analysts anticipate that Marinus Pharmaceuticals Inc. will post ($1.47) EPS for the current year.

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.